Scarica l'app Stockscreener
31.73
35.24%
-17.27
Dopo l'orario di chiusura:
32.00
0.27
+0.85%
Precedente Chiudi:
$49.00
Aprire:
$40
Volume 24 ore:
8.24M
Relative Volume:
13.17
Capitalizzazione di mercato:
$1.53B
Reddito:
$2.50M
Utile/perdita netta:
$-86.49M
Rapporto P/E:
-14.07
EPS:
-2.2544
Flusso di cassa netto:
-
1 W Prestazione:
-34.54%
1M Prestazione:
-32.82%
6M Prestazione:
+20.42%
1 anno Prestazione:
+172.83%
Intervallo 1D:
$29.77
$41.00
Intervallo di 1 settimana:
$29.77
$50.70
Portata 52W:
$6.71
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Nome
Maze Therapeutics Inc
Settore
Industria
Telefono
(650) 850-5070
Indirizzo
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
31.73 | 2.36B | 2.50M | -86.49M | 0 | -2.2544 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Iniziato | Truist | Buy |
| 2026-03-10 | Iniziato | Mizuho | Outperform |
| 2025-12-04 | Iniziato | Wells Fargo | Overweight |
| 2025-11-14 | Iniziato | Raymond James | Outperform |
| 2025-09-02 | Iniziato | BTIG Research | Buy |
| 2025-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Maze Therapeutics Inc Borsa (MAZE) Ultime notizie
Maze Therapeutics' (MAZE) "Buy" Rating Reiterated at BTIG Research - MarketBeat
Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829 - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Mizuho reiterates Maze Therapeutics stock rating on phase 2 data By Investing.com - Investing.com Australia
Truist reiterates Buy on Maze Therapeutics stock after trial data By Investing.com - Investing.com Canada
Maze Therapeutics posts trial data for lead drug (MAZE:NASDAQ) - Seeking Alpha
HC Wainwright Raises Maze Therapeutics (NASDAQ:MAZE) Price Target to $110.00 - MarketBeat
Mizuho reiterates Maze Therapeutics stock rating on phase 2 data - Investing.com
Leerink reiterates Maze Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Why Maze Therapeutics Stock Is Sinking After Good News - TipRanks
Maze Therapeutics stock soars 22% on positive trial data for MZE829 - Investing.com
Maze Therapeutics adds Neil Kumar to board leadership - TipRanks
Earnings Flash (MAZE) Maze Therapeutics Posts Q4 Net Loss $0.65 a Share, vs. FactSet Est of $0.72 Loss - marketscreener.com
Maze Therapeutics 2025 10-K: Revenue $0M, EPS $(3.05) - TradingView
Maze appoints Neil Kumar to its board as Class I director - TradingView
Maze Therapeutics Inc. unveils encouraging results for MZE829 APOL1 inhibitor in AMKD patients - Traders Union
Maze Therapeutics reports bigger-than-expected Q4 loss on higher R&D costs - TradingView
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease - The Manila Times
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights - Bluefield Daily Telegraph
Maze Therapeutics Announces Positive Topline Data from - GlobeNewswire
Portfolio Shifts: What analysts say about Maze Therapeutics Inc stockFed Meeting & AI Driven Price Forecasts - baoquankhu1.vn
This Evommune analyst begins coverage on a bullish note; here are top 5 initiations for Wednesday - MSN
This strategy analyst begins coverage on a bullish note; here are top 5 initiations for Tuesday - MSN
Maze Therapeutics (MAZE) Executive Stock Sale & 2026 Company PerformanceNews and Statistics - IndexBox
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears - Yahoo Finance
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears - The Motley Fool
Harold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - MarketBeat
Maze Therapeutics president Bernstein sells $736k in stock By Investing.com - Investing.com Canada
Maze Therapeutics (NASDAQ:MAZE) Upgraded to "Strong-Buy" at Truist Financial - MarketBeat
Truist Securities initiates coverage of Maze Therapeutics (MAZE) with buy recommendation - MSN
Fundamentals Check: What analysts say about Maze Therapeutics Inc stockEarnings Growth Summary & Weekly High Potential Stock Alerts - baoquankhu1.vn
Wells Fargo initiates coverage of Maze Therapeutics (MAZE) with overweight recommendation - MSN
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Truist initiates Maze Therapeutics stock coverage with buy rating By Investing.com - Investing.com Canada
Maze Therapeutics (NASDAQ:MAZE) Sets New 1-Year High After Analyst Upgrade - Defense World
Maze Therapeutics (NASDAQ:MAZE) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Foresite Capital Management IV LLC Sells 1,589,262 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Foresite Capital Management V LLC Sells 258,900 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics, Inc. News — NASDAQ:MAZE - TradingView
Boothbay Fund Management LLC Acquires 276,345 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
545,132 Shares in Maze Therapeutics, Inc. $MAZE Acquired by ArrowMark Colorado Holdings LLC - MarketBeat
Maze Therapeutics stock hits all-time high at 49.28 USD By Investing.com - Investing.com Nigeria
Maze Therapeutics (NASDAQ:MAZE) Upgraded at Mizuho - Defense World
Assessing Maze Therapeutics (MAZE) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Maze Therapeutics (NASDAQ:MAZE) Rating Increased to Strong-Buy at Mizuho - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) CMO Sells 30,000 Shares - MarketBeat
Maze Therapeutics Executive Sells All Common Stock Holdings - TradingView
Maze Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Maze Therapeutics stock hits all-time high at 49.28 USD - Investing.com Australia
Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month HighShould You Buy? - MarketBeat
Maze Therapeutics Inc Azioni (MAZE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Maze Therapeutics Inc Azioni (MAZE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bernstein Harold | President, R&D & CMO |
Mar 20 '26 |
Sale |
49.10 |
15,000 |
736,439 |
0 |
| Bernstein Harold | President, R&D & CMO |
Mar 10 '26 |
Option Exercise |
10.42 |
30,000 |
312,600 |
30,000 |
| Bernstein Harold | President, R&D & CMO |
Mar 10 '26 |
Sale |
50.45 |
30,000 |
1,513,560 |
0 |
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):